TASIGNA200mg

TASIGNA (Nilotinib) 200mg hard capsules by Novartis is a powerful second-generation BCR-ABL tyrosine kinase inhibitor (TKI) that is approximately 30 times more potent than imatinib (Gleevec) against BCR-ABL in vitro. FDA-approved in 2007, Tasigna has become a cornerstone treatment for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Nilotinib works by selectively binding to the ATP-binding site of the BCR-ABL fusion protein — the oncogenic driver created by the Philadelphia chromosome translocation t(9;22). By blocking BCR-ABL kinase activity, nilotinib shuts down downstream signaling pathways essential for leukemic cell survival, leading to apoptosis and disease control. Tasigna is the first and only CML drug with FDA-approved treatment-free remission (TFR) data. In the ENESTfreedom and ENESTop studies, approximately 50% of patients who achieved sustained deep molecular response (MR4.5) could successfully discontinue treatment while maintaining remission — a groundbreaking achievement toward functional cure of CML. As a licensed pharmaceutical supplier based in Turkey, we provide authentic Novartis Tasigna with competitive wholesale pricing for hospitals, hematology clinics, oncology centers, and pharmaceutical distributors worldwide. Contact us via WhatsApp for current pricing and availability.